The Christianson syndrome protein, sodium hydrogen exchanger isoform 6, is required for fat accumulation
The Journal of Physiology · 2025
DOI: 10.1113/jp289613 ↗At a glance
Journal article in The Journal of Physiology, 2025. Written by Ruby Gupta and 7 co-authors. Institution: Department of Physiology, Pharmacology and Therapeutics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Major MEDLINE topics: Sodium-Hydrogen Exchangers, Intellectual Disability, Ataxia, Genetic Diseases, X-Linked. Cited 2 times so far (Crossref); 70 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NINDS NIH HHS, NIGMS NIH HHS, American Diabetes Association.
Abstract (original language)
Mutations in NHE6 (human gene name SLC9A6 ) lead to the rare X‐linked disorder Christianson syndrome (CS) characterized by intellectual disability, autism and ataxia. NHE6 is a Na + /H + exchanger that regulates pH and ionic equilibria across endosomal membranes in a variety of tissues, although its non‐neuronal role is understudied. A common co‐morbidity in CS is low body weight, with body mass index in the 3–5th percentile range. In the present study, we use a Nhe6 KO mouse model of CS to demonstrate a role for NHE6 in fat accumulation and glucose homeostasis. On both chow and a high‐fat diet, Nhe6 KO mice displayed lower body weight and decreased fat accumulation in adipose tissue. By contrast, glycogen accumulation was strongly increased in liver of Nhe6 KO mice on a high‐fat diet. Knockdown of NHE6 (NHE6 KD) in 3T3L1 adipocytes resulted in smaller lipid droplets, pointing to a cell autonomous role in fat accumulation. NHE6 KD adipocytes also exhibit dysregulation of insulin‐responsive uptake of fatty acids, glucose and Fe/transferrin, as well as the cell surface translocation of the corresponding transporters. Furthermore, we observed selective downregulation of key components of the insulin signalling pathway that could be restored using the Na + /H + exchanger mimetic monensin or the V‐ATPase inhibitor bafilomycin, pointing to pH dysregulation as the underlying defect. These findings establish NHE6 as a novel contributor to energy metabolism with implications for CS patients. image Key points NHE6 is an endosomal Na + /H + exchanger mutated in Christianson syndrome. Nhe6 null mice accumulate less fat and weigh less than control animals. In adipocytes, NHE6 knockdown reduces insulin‐stimulated fatty acid and glucose uptake. NHE6 exerts proteostatic control over multiple components of the insulin signalling pathway.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Physiology, Pharmacology and Therapeutics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
ORCID profiles: Ruby Gupta, Allatah X Mekile, Cory J White, Damaris N Lorenzo, Rajini Rao
Funding
- NINDS NIH HHS
- NIGMS NIH HHS
- American Diabetes Association
Cite
APA
Gupta, R., Mekile, A. X., Patnayak, R. L., Makena, M. R., Bowman, R. W., White, C. J., Lorenzo, D. N., & Rao, R. (2025). The Christianson syndrome protein, sodium hydrogen exchanger isoform 6, is required for fat accumulation. The Journal of Physiology. https://doi.org/10.1113/jp289613
Vancouver
Gupta R, Mekile AX, Patnayak RL, Makena MR, Bowman RW, White CJ, et al. The Christianson syndrome protein, sodium hydrogen exchanger isoform 6, is required for fat accumulation. The Journal of Physiology. 2025. doi:10.1113/jp289613
BibTeX
@article{Gupta2025,
author = {Gupta, Ruby and Mekile, Allatah X and Patnayak, Rachana L and Makena, Monish Ram and Bowman, Ray Wesley and White, Cory J and Lorenzo, Damaris N and Rao, Rajini},
title = {The Christianson syndrome protein, sodium hydrogen exchanger isoform 6, is required for fat accumulation},
journal = {The Journal of Physiology},
year = {2025},
doi = {10.1113/jp289613}
}
EUVIMED